Clostridial neurotoxins with altered persistency

1. A polypeptide comprising:

(a) a heavy chain (HC) domain of a neurotoxic component of a clostridial toxin;

(b) a first light chain (LC) domain of a neurotoxic component of a clostridial toxin; and

(c) at least one further LC domain of a neurotoxic component of a clostridial toxin;

wherein the domains are connected by a direct linkage via a covalent bond, a peptide-linker, a chemical linker, or a combination of two or more thereof, and wherein the first and at least one further LC domains may be the same or different from each other, and wherein each of the first and at least one further LC domains exhibit proteolytic activity.

2. The polypeptide of claim 1 , wherein the HC domain, the first LC domain, or the at least one further LC domain comprise at least one modification selected from the group consisting of a phosphorylation, a pegylation, a glycosylation, a sulfatation, a methylation, an acetylation, a lipidation, a myristoylation, a palmitoylation, an isoprenylation, a linkage of glucosyl-phophatidylinositol, a hydroxylation, an amidation, and a tag-sequence.

3. The polypeptide of claim 1 , wherein both the HC domain and an LC domain comprise at least one modification selected from the group consisting of a phosphorylation, a pegylation, a glycosylation, a sulfatation, a methylation, an acetylation, a lipidation, a myristoylation, a palmitoylation, an isoprenylation, a linkage of glucosyl-phophatidylinositol, a hydroxylation, an amidation, and a tag-sequence.

4. The polypeptide of claim 1 , wherein the polypeptide is selected from Light Chain Botulinum neurotoxin type A-Light Chain Botulinum neurotoxin type A-Heavy Chain Botulinum neurotoxin type A (LCBoNT/A-LCBoNT/A-HCBoNT/A); Light Chain Botulinum neurotoxin type C-Light Chain Botulinum neurotoxin type A-Heavy Chain Botulinum neurotoxin type A (LCBoNT/C-LCBoNT/A-HCBoNT/A); Light Chain Botulinum neurotoxin type B-Light Chain Botulinum neurotoxin type A-Heavy Chain Botulinum neurotoxin type A (LCBoNT/B-LCBoNT/A-HCBoNT/A); Light Chain Botulinum neurotoxin type A-Light Chain Botulinum neurotoxin type C-Heavy Chain Botulinum neurotoxin type C (LCBoNT/A-LCBoNT/C-HCBoNT/C); Light Chain Botulinum neurotoxin type C-Light Chain Botulinum neurotoxin type C-Heavy Chain Botulinum neurotoxin type C (LCBoNT/C-LCBoNT/C-HCBoNT/C); Light Chain Botulinum neurotoxin type B-Light Chain Botulinum neurotoxin type C-Heavy Chain Botulinum neurotoxin type C (LCBoNT/B-LCBoNT/C-HCBoNT/C); and Light Chain Tetanus neurotoxin-Light Chain Botulinum neurotoxin type A-Heavy Chain Botulinum neurotoxin type A (LCTeNT-LCBoNT/A-HCBoNT/A).

5. A composition comprising the polypeptide of claim 1 .

6. The composition of claim 5 further comprising a pharmaceutically acceptable carrier.

7. The composition of claim 5 further comprising a pH buffer, an excipient, a cryoprotectant, a preservative, an analgesic, a stabilizer or any combination thereof.

8. A method of treating a human or animal afflicted with a condition treatable with a Clostridium botulinum toxin, comprising administering to the human or animal, a treatment effective amount of the polypeptide of claim 1 .

9. The method of claim 8 , wherein the condition treatable with a Clostridium botulinum toxin is a cosmetic condition.

10. The method of claim 8 , wherein the condition treatable with a Clostridium botulinum toxin is associated with hyperactive cholinergic innervations of a muscle or an exocrine gland.

11. The method of claim 8 , wherein the polypeptide blocks acetylcholine secretion into the synaptic cleft.